Chronic post-groin surgery orchialgia represents a challenge for the managing physicians and is a burden on the quality of life of the patients. It has been reported that the incidence of chronic post-inguinal herniorrhaphy pain of moderate to severe nature resembles 10–12% (1), and the daily life activities are affected in approximately 0.5–6% (2). Chronic orchialgia of various etiologies affects up to 10–12% of the patients (1) and represents a significant burden on their quality of life.
100,000 men in the US yearly. In the UK, the incidence has been estimated to be around 1% (3).

Chronic post-surgical pain in the groin region is mostly due to injury or entrapment of the ilioinguinal and/or the genitofemoral nerves during surgical dissections (4). Unfortunately, the anti-neuropathic medications currently in use, such as some anti-depressants and anti-convulsants, have several drawbacks, specifically excessive sedation and drowsiness (5). Results of randomized controlled trials have yielded that patients persist to have, on average, a pain of moderate severity despite taking their prescribed pain medications (6).

A diversity of interventional options currently exists with variable efficacy, such as nerve block with local anesthetic and steroids, cryoaulation, transcutaneous electrical nerve stimulation, surgical neurectomy, and orchidectomy (7).

The promising results of radiofrequency (RF) technology have attracted the attention of pain clinicians to use it in many chronic pain conditions (8). The usage of pulsed radiofrequency (PRF) in the treatment of chronic groin pain and orchialgia has been reported in limited case series (9-12).

The aim of this study is to evaluate the analgesic efficacy of PRF applied to the ilioinguinal nerve and the genital branch of the genitofemoral nerve for patients suffering from chronic post-surgical orchialgia.

**Methods**

This study was approved by the ethical committee of the faculty of medicine, and written informed consent was obtained from each patient. Seventy adult men complaining of chronic post-surgical orchialgia of at least 3 months that were referred from the andrology clinic to our interventional pain unit were consecutively enrolled. The trial was registered at www.anzctr.org.au, and the identification number for the registry is: ACTRN12616000649415.

The inclusion criteria were patients with chronic scrotal pain (orchialgia) that fulfilled the following criteria: 1) pain intensity ≥ 5 on the visual analog scale (VAS), 2) pain that lasted for more than 3 months after groin surgeries, 3) failed conservative treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), and 4) showed more than 50% reduction of their orchialgia on the VAS for at least 6 hours following spermatic cord block with 6 mL of lidocaine 2%.

The exclusion criteria were: 1) patients with other causes of scrotal pain, e.g., epididymitis, orchitis, and hydrocele, 2) patients complaining of groin infection and coagulopathy, 3) patients suffering from hypertension, ischemic heart disease, or psychiatric disorders, and 4) patients allergic to study medications and concomitant use of NSAIDs or monoamine oxidase inhibitors.

The patients were randomly allocated to 2 groups by using a computer-created number list, which was concealed in sealed envelopes without blocking, and they were open by the researcher before application of the procedure.

The PRF group (n = 35) was the interventional group, in which PRF was applied to the ilioinguinal nerve and the genital branch of the genitofemoral nerve using a NeuroTherm 2000 RF generator (Neuro-Therm, Inc., Wilmington, MA). We sterilized the lower abdomen from the umbilicus to the scrotum, then we started the ultrasound (US) scanning using an M-Turbo machine (SonoSite, Inc., Bothell, WA) with a superficial linear probe 10 HZ frequency. The scanning process was implemented from the anterior superior iliac spine, keeping the shadow of iliac bone in view. The ilioinguinal nerve was identified in the fascial splitting area between the fascia transversalis and internal oblique muscles, just medial to the shadow of iliac bone (Fig. 1). A 22-gauge, 10 cm RF needle with a 10 mm active tip was introduced out of plane towards the nerve, and localization was further confirmed by producing a groin pain at 50 HZ and less than 0.5 volt sensory stimulation and contraction of the lower outer quadrant of the abdominal muscles at 2 HZ and less than 1 volt motor stimulation. After satisfactory needle position was confirmed, PRF was initiated using the following parameters: voltage output:
Pulsed Radiofrequency for Chronic Post-Surgical Orchialgia

40–60 V; 2 Hz frequency; 20 ms pulses in a one-second cycle, 120 second duration per cycle and 42°C plateau temperature. PRF was applied for 4 cycles. The genital branch of the genitofemoral nerve was targeted under US guidance with the same probe, where the assistant held the testis and the cord and the probe was applied transversely just distal to the external inguinal ring; the deferent duct is visible as a non-compressible, internal hypoechoic structure with a hyperechoic horizon (Fig. 2). A 22-gauge, 10 cm RF needle with a 10 mm active tip was advanced out of plane just lateral to the deferent duct and manipulated to achieve scrotal pain at 50 Hz and less than 0.5 volt sensory stimulation. After localization of the nerve, PRF was commenced with the same parameters applied for the ilioinguinal nerve.

The sham group (n = 35) was the control group, and the same procedure applied for the interventional group was done without giving PRF. The procedure was done by a senior staff pain clinician.

Two weeks following the procedure, the postoperative analgesic protocol was started and consisted of either duloxetine tablets initiated at a dose of 30 mg, increased up to 60 mg according to the response as a first drug treatment, and/or pregabalin initiated at a dose of 50 mg, titrated according to the efficacy and side effects every week as a second drug treatment, and/or tramadol initiated at a dose of 50 mg titrated according to efficacy and side effects as a third drug treatment. The postoperative follow-up (regarding pain assessment and treatment protocol) was accomplished by a pain clinician blinded to the study intervention.

The primary outcome variable was the percentage of patients that showed > 50% reduction of their VAS pain score (from baseline values), measured at 3 months post-procedure. The secondary outcome variables were the scrotal pain intensity measured by a VAS, the percentage of patients that did not require additional postoperative analgesics, the total analgesic consumption (duloxetine, pregabalin, or tramadol), and the global perceived effect (GPE) during the 3-month follow-up period. The GPE was assessed by a 7-point Likert-like verbal rating scale where: extremely dissatisfied = 1, dissatisfied = 2, somewhat dissatisfied = 3, undecided = 4, somewhat satisfied = 5, satisfied = 6, and extremely satisfied = 7.

Statistical Analysis

The statistical analysis was carried out on a personal computer using SPSS Version 22.0 (IBM Corporation, Armonk, NY). Normality of continuous data distribution was tested with the Anderson-Darling test prior to further statistical analysis. Categorical data were described as number and percent, and comparisons were made by chi-square and Fisher’s exact tests. Continuous data were described as mean ± standard deviation (SD) or 95% confidence interval (CI), and point-by-point comparison was done by unpaired Student’s t-test. A linear mixed-effects model for repeated measures was used for analysis of VAS pain scores over time (2, 4, 6, 8, and 12 weeks post-procedural), examining the following effects: group, time, and group-by-time interaction, followed by post-hoc test with Bonferroni correction for multiple comparisons. Medians and interquartile ranges were used for skewed data (GPE), and comparisons were made using the Mann-Whitney U test. \( P < 0.05 \) was considered statistically significant.

Based on a retrospective analysis of our institutional work, we found that 75% of patients treated with PRF, in comparison to 33% of patients managed with medical treatment, showed more than 50% reduction of VAS pain score from baseline values. Using these assumptions, the estimated sample size for the 2-sample comparison of percentages revealed a minimum sample size of 28 patients in each study group would achieve a power of 80%, assuming a type I error of 0.05. We enrolled 35 patients in each group to allow for drop-outs.

Fig. 2. Sonoanatomy of the spermatic cord with its contents at the external inguinal ring. 1 = the deferent duct; 2 = the spermatic artery; 3 = the pampiniform plexus of veins; 4 = the pubic tubercle; 5 = the spermatic fascia.
Results

Eighty patients were assessed for eligibility, 10 patients were excluded due to unsatisfactory response to spermatic cord block, 4 patients were lost to follow-up, 6 patients were excluded due to protocol violation, and 60 patients (30 in each group) remained for the analysis (Fig. 3).

There was not a statistically significant difference among the 3 groups with respect to demographic data and patient characteristics (Table 1).

The percentage of patients that showed > 50% reduction of their VAS pain score was 80% (24/30) in the PRF group, compared to 23.33% (7/30) in the sham group. The percentage of patients that did not require additional analgesic treatment was 50% (15/30) in the PRF group, compared to 3.3% (1/30) in the sham group. The percentage of patients that required duloxetine at a dose of 30 mg was 33.3% (10/30) in the PRF group, compared to 53.3% (16/30) in the sham group, and duloxetine at a dose of 60 mg was required in 16.7% (5/30) of patients in the PRF group, compared to 30% (9/30) of patients in the sham group. Three patients in the sham group required duloxetine 60 mg + pregabalin 100 mg and one patient required duloxetine 60 mg + pregabalin 150 + tramadol 100 mg (Table 2).

The linear mixed model analysis of VAS pain scores revealed a significant reduction of the mean overall VAS pain score over time between the groups (P < 0.01), with a significant time and group-by-time interaction. Moreover, there was a significant reduction of the mean VAS score (between groups) at all of the measured time-points (2, 4, 6, 8, and 12 weeks post-procedure) (P = 0.001) in the PRF group in comparison to the sham group (Table 3).

There was a significant improvement of the GPE in the PRF group in comparison to the sham group, evaluated after 6 and 12 weeks post-procedure, respectively (median, interquartile range) [6(4:7)] vs. [4(1:7)] and [6(3:7)] vs. [4(2:7)] (P = 0.00) (Fig. 4).

Discussion

In this randomized, double-blind, sham-controlled, clinical trial, we found that PRF applied to the ilioinguinal nerve and the genital branch of the genitofemoral nerve for patients suffering from chronic postsurgical orchialgia significantly reduced pain intensity and decreased the demand for pain medications during a 3-month follow-up period.

In agreement with our results, Venkataparthasarathy and Ather (11), in their retrospective analysis of 15 cases of ilioinguinal and genitofemo-
Pulsed Radiofrequency for Chronic Post-Surgical Orchialgia

Rah neuralgia treated with PRF on the appropriate nerve (ilioinguinal or genitofemoral), showed that the mean VAS pain score was reduced from 7.5 pre-procedure to 3.2 at 6 months post-procedure, and the number of patients that did not require additional post-procedure analgesic medications was 6. Moreover, Cohen and Foster (9) performed PRF on ilioinguinal or genitofemoral nerves for 3 patients complaining of groin pain or orchialgia, and they reported a complete post-procedure pain resolution during a 6-month follow-up period.

In contrast to the previously mentioned studies, the current study is unique in its design that is sham-controlled, which is intrinsically difficult in chronic pain management. Furthermore, we included only the patients who showed more than 50% reduction of their VAS pain score in response to diagnostic spermatic cord block, to exclude patients with psychiatric problems, as well as secondary gain with malingering associated with chronic pelvic pain and to be sure that the pain signals came from the nerves in the cord and were not a referred pain from a mid-ureteral stone, inguinal hernia, aortic or common iliac artery aneurysms, or lower back disorders.

Several neurodestructive techniques, such as surgical rhizotomy, chemical neurolysis, and cryoablation, have been employed in the management of chronic pain states with variable efficacy (13). Cryoablation has been shown to provide effective, long-lasting pain relief when applied to peripheral nerves (14,15). Unfortunately, the analgesic efficacy and duration of cryoablation depend basically on the extent of cold-induced axonal damage of neuronal tissue; thus, application of cryoablation to nerves such as the ilioinguinal and genitofemoral nerves that provide sensation to the genital region is unfavorable practice in interventional pain management.

The RF technology has gained wide spread use in interventional pain management. It has been conventionally used for interruption of pain impulses through heat-induced neurodestruction (16). Although conventional RF has a clear effective and long-standing pain relief, it carries the risks of dysthesia, sensory loss, and motor weakness. Such drawbacks make its application on peripheral nerves undesirable (17). In contrast, PRF is an alternative mode that interrupts the pain impulses through biological changes rather than neurodestruction (18).

To improve the antinociceptive effect of PRF, we applied it for an extended duration, 4 rounds of 120 seconds each rather than one round (120 seconds) that is repeatedly mentioned in previous studies (8). In this context, animals subjected to increased exposure time from 2 to 6 minutes showed a significant antiallodynic effect without motor impairment (19). In our follow-up period, we did not report any neuropathic symptoms or signs related to the usage of PRF apart from some tingling sensations at the site of needle entry in a few patients that disappeared spontaneously within 4 or 5 days post-procedure.

Chronic post-surgical chronic scrotal pain or orchialgia is essentially due to unintentional injury or entrapment of the ilioinguinal and the genital branch of the genitofemoral nerve at the surgical site in their course at the groin region (Fig. 5), so interruption of pain impulses carried by these nerves by PRF was the main target in the current study.
In this study, we clearly identified the ilioinguinal nerve under US guidance, just medial to the anterior superior iliac spine, in the fascial splitting area between internal oblique muscle and fascia transversalis, and further confirmation was achieved through nerve stimulation. In contrast, the genital branch of the genitofemoral nerve is a small nerve embedded in the fascial coverings of the spermatic cord (20) that could not be visualized by the US; alternatively, we placed the RF needle on the lateral region of the spermatic cord, which is a common course of the genital nerve, and advanced medially to pick it with the nerve stimulator.

In contrast to the mechanism by which corticotrophin-releasing factor controls pain, that is tissue thermocoagulation, the anti-allodynic mechanism of PRF is unclear, but it may involve a temperature-independent effect mediated by a rapidly changing electrical field (21). Sandkühler and colleagues (22) identified a robust long-term depression of synaptic transmission in substantia gelatinosa neurons that can be induced by a low-frequency stimulation of the primary afferent A-delta fibers. In this context, Van Zundert et al (23) demonstrated an increase of c-fos expression in the dorsal horn cells after exposure of the cervical dorsal root ganglion to different RF modalities, which was not temperature dependent. Moreover, Hagiwara and associates (24) claimed that the analgesic action of PRF involves an enhancement of the noradrenergic and the serotonergic descending pain inhibitory pathways in an experimental pain model.

Regarding postoperative analgesic protocol, we assumed (from our anecdotal experience) that combination of multiple drugs is more beneficial than a maximum effective dose of each drug (5,25). Therefore, we did not increase the dose of duloxetine above 60 mg or pregabalin above 150 mg, and we preferred combination treatment to improve the patient’s compliance and minimize side effects, which is consistent with the general concept of management of chronic neuropathic pain (6,26).

We cannot deny that duloxetine was able to reduce the pain intensity significantly by time, but the GPE was significantly better in the PRF group. Duloxetine is a serotonin-norepinephrine reuptake inhibitor; its exact analgesic action in human is unknown. It is suggested that duloxetine increases the level of serotonin and norepinephrine in synaptic clefts at the spinal and the supra-spinal levels, activating the descending pain inhibitory system (27).

This study was limited by the follow-up period, which was only 3 months.

**Conclusions**

For patients suffering from chronic post-surgical orchialgia, PRF applied to the ilioinguinal nerve and the genital branch of the genitofemoral nerve is an effective treatment modality. It provides long-lasting pain relief and decreases the demand for pain medications.
References


